• search
Development and Manufacturing Development and Manufacturing

Development and Manufacturing

We are committed to providing high-quality and flexible scale development and manufacturing services for large molecules and CGT.

APSL is rapidly positioning itself to provide end-to-end integrated development and manufacturing offerings in traditional and advanced drug modalities. Our mAb and protein therapeutics development is supported by in-house physiochemical and bio analytical development. We have a state-of-the-art cGMP viral vector manufacturing facility being commissioned.

Our manufacturing services cater to both GMP and non-GMP manufacturing for preclinical development as well as GMP operations to support clinical or commercial needs for any recombinant protein expressed in suspension mammalian culture or E coli.

We have technological flexibility in both stainless steel and single-use bioreactor systems, as well as ability to undertake alternating tangential flow for commercial scale manufacturing.

We undertake an integrated approach to our quality management system that enables greater flexibility and leverage pan – organization experience in managing regulatory audits.

Speak to our experts

mAb and protein therapeutics

We provide comprehensive capabilities for mAb & protein therapeutics development. It is supported by in-house physiochemical and bio analytical development. Our strength is built on a deep understanding of cell culture, protein chemistry and an integrated analytics platform enabling a robust, scalable, controlled process.

Our approach to mAb and protein therapeutics development is based on a balance of ‘Productivity, Quality and Stability’. This approach is enabled by a collaboration between the Molecular Biology and the Analytical teams to maximize the long-term sustainability of clones and proteins.

Plasmid

Aurigene Pharmaceutical Services provide Plasmid DNA production service. We provide both Research grade and GMP ready plasmids.

Research grade plasmids are used for in vitro applications in cloning, mutagenesis, microbial transformation and protein production. GMP ready plasmids are used in IVT mRNA, protein & mAb production, stable cell line generation, bacmid generation, viral packaging, vaccine, gene therapy studies and animal immunization.

Production scale:

  • Small-scale (0.1 to 1 mg)
  • Medium-scale (up to 10 mg)
  • Large-scale (100 mg to 1 g)

Viral Vectors

GMP manufacturing capability supports any pre-clinical, clinical and commercial scale manufacturing of a wide range of viral vector platforms – Lenti, Adeno, Retro and Baculo.

Driven by scale flexibility, we can support on a wide scale of operation – 0.5L – 1,000L. Utilization of Single Use technologies enable prompt change over by omitting cleaning validation.

We undertake an Integrated approach to Safety and Quality management systems, which enable greater flexibility by leveraging pan – organizational experience in managing Regulatory audits & Compliance to statutory norms.

Analytical

Analytical services are used to identify, isolate or quantify molecules and to characterize their physical properties. Aurigene provides physiochemical and biological characterization services.

Backed by our strong protein chemistry background, we enable ‘Finger-Print’ protein structure and functional characterization for proteins from naked proteins to hyper-glycosylated or derivatized proteins.

Our Biological characterization capability enables a sound understanding of the biological mechanism of action of the product. We can support a wide variety of biological assays including, cell-proliferation/killing, binding affinity, cell signaling and viability or endpoint assays using both transformed cell lines and primary cells.

Fill Finish

With over 10,000 Sq. Meters of Fill Finish footprint, we can support filling of a wide range of presentations – Vials (Liquid and Lyophilized), Pre-filled Syringes and Autoinjectors.

Automation equipped; our filling capability addresses – Hi Accuracy – Hi Concentration – Hi Viscosity – Lo Volume – protein filling. End-to-end Single Use capability enables for faster change over and assurance of cleaning validation.

Our integrated approach to quality management systems enables greater flexibility and leverage pan -organization experience in managing regulatory audits.

Why Aurigene Development and Manufacturing Services?

High quality and flexible scale production

Design of Experiments (DoE) and Quality by Design (QbD)approach

One Stop Solution

Development supported by digital infrastructure

Integrated approach to Safety and Quality management systems

Integrated QC Testing and Release

Diverse platform of instruments and technologies

In-house capability across the value chain with a trained scientific staff

Other Services

Virtual Tour

 

Connect with our scientific experts for your drug discovery, development, and manufacturing needs

We understand that clear communication is essential to successful collaborations, and that's why we have a dedicated team that is always ready to help you. Whether you have questions about our services, want to discuss a potential partnership, or simply want to learn more about our company, we're here to help.

Our team of experts is dedicated to providing personalised solutions tailored to your unique needs. So, please don't hesitate to reach out to us. We look forward to hearing from you and helping you achieve your business goals.

Country
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Resources

PROTACs: Research for a life without cancer

OCTOBER 01, 2024

PROTACs: Research for a life without cancer

PROTACs: Proteolysis-targeting chimeras (PROTACs) are a rapidly evolving field with promising applications in cancer, neurodegenerative diseases, and other conditions where the regulation of protein levels is crucial. PROTACs are a novel class of small molecules designed to target specific proteins for degradation by the ubiquitin-proteasome sys...

Read More
View All

Advancement in personalized medicine and how the CRDMO industry is part of the solution

Personalized medicine is transforming the healthcare landscape by customizing treatment plans to individual patients’ unique genetic, clinical and environmental characteristics. These are effective and less invasive treatments for a wide range of conditions. Contract Research, Development and Manufacturing Organizations (CRDMOs) play an important role...

Read More
View All

Cell Line Development

We enable development of stable and high yielding recombinant Mammalian and Microbial lines. ...

Read More
View All

Case study: Tackling CYP 2C9 inhibition challenges

The Problem: Active compounds in a project were found to be highly potent inhibitors of CYP 2C9 The compounds selectively inhibited CYP 2C9 with IC50 values <100 nM There was no considerable inhibition of the other CYP isoforms Our Mitigation Approach: CYP 2C9 inhibition data was generated for a larger set of co...

Read More
View All

Synthesis of Anti-covid Drug Nirmatrelvir Using Flow Chemistry

2022

Synthesis of the anti-covid therapeutic Nirmatrelvir by using flow chemistry to enhance efficiency of amide to nitrile conversion in a functionally and Stereochemically Embellished environment. ...

Read More
View All
×

You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.

If you wish to continue to this external website, click Proceed.

ProceedBack

X

Leaving already?

Don't forget to join us at

CPHI Worldwide 2023.

October 24th-26th, 2023 | Barcelona, Spain

Get ready to accelerate your drug’s journey to the market